REGN:NGS-Regeneron Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 978.21

Change

-6.43 (-0.65)%

Market Cap

USD 42.08B

Volume

0.59M

Analyst Target

USD 674.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B
BMRN Biomarin Pharmaceutical Inc

-3.23 (-4.62%)

USD 13.32B

ETFs Containing REGN

EMEH:SW BNP Paribas Easy Energy &.. 8.55 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 8.30 % 0.00 %

-0.06 (-0.65%)

N/A
BTEC:SW iShares Nasdaq US Biotech.. 8.28 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 8.14 % 0.35 %

-0.05 (-0.65%)

USD 0.45B
IBB iShares Biotechnology ETF 6.77 % 0.47 %

-0.01 (-0.65%)

USD 7.39B
IBBQ Invesco Nasdaq Biotechnol.. 6.71 % 0.00 %

-0.11 (-0.65%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 6.65 % 0.00 %

N/A

USD 0.52B
FPXU:PA First Trust US Equity Opp.. 6.60 % 0.00 %

+0.43 (+-0.65%)

USD 6.29M
CURG:LSE VanEck Genomics and Healt.. 6.57 % 0.00 %

+0.06 (+-0.65%)

USD 5.12M
2B70:XETRA iShares Nasdaq US Biotech.. 6.51 % 0.00 %

-0.02 (-0.65%)

USD 0.52B
SPQH:XETRA Global X S&P 500® Quarte.. 4.95 % 0.00 %

-0.09 (-0.65%)

USD 0.05B
ZWHC:CA BMO Covered Call Health C.. 4.73 % 0.00 %

-0.20 (-0.65%)

N/A
BIB ProShares Ultra Nasdaq Bi.. 4.71 % 0.95 %

-0.61 (-0.65%)

USD 0.09B
UBIO 4.54 % 0.95 %

N/A

N/A
EGUSAS:SW UBS (Irl) Fund Solutions .. 4.35 % 0.00 %

N/A

USD 0.10B
SYNB Putnam Biorevolution ETF 4.33 % 0.00 %

+0.03 (+-0.65%)

USD 5.72M
MEDX Horizon Kinetics Medical .. 4.26 % 0.00 %

-0.39 (-0.65%)

N/A
PINK Simplify Exchange Traded .. 4.19 % 0.00 %

-0.34 (-0.65%)

USD 0.19B
XGSD:SW Xtrackers Stoxx Global Se.. 4.17 % 0.00 %

-0.32 (-0.65%)

USD 0.67B
XGSD:XETRA Xtrackers Stoxx Global Se.. 4.17 % 0.00 %

-0.30 (-0.65%)

N/A
XDNA:CA iShares Genomics Immunolo.. 4.15 % 0.00 %

+0.03 (+-0.65%)

CAD 5.23M
BIS ProShares UltraShort Nasd.. 4.13 % 0.95 %

+0.17 (+-0.65%)

USD 3.26M
HEAL:CA 3.97 % 0.00 %

N/A

N/A
IDNA iShares Genomics Immunolo.. 3.97 % 0.00 %

+0.08 (+-0.65%)

USD 0.14B
FDG American Century ETF Trus.. 3.60 % 0.00 %

-0.01 (-0.65%)

N/A
XOVR SPDR BOFA MERRILL LYNCH C.. 3.58 % 0.00 %

-0.11 (-0.65%)

USD 0.11B
CAPS:LSE First Trust Capital Stren.. 2.26 % 0.00 %

-2.50 (-0.65%)

N/A
PFUT Putnam Sustainable Future.. 1.93 % 0.00 %

-0.09 (-0.65%)

USD 0.31B
XLVE:CA Mulvihill U.S. Health Car.. 1.84 % 0.00 %

-0.02 (-0.65%)

N/A
SMRT:PA 0.53 % 0.00 %

N/A

N/A
SM8T:XETRA Amundi Index Solutions - .. 0.53 % 0.00 %

-3.60 (-0.65%)

USD 0.04B
SMRU:PA Amundi Index Solutions - .. 0.53 % 0.00 %

+0.06 (+-0.65%)

USD 3.56M
ACWV 0.00 % 0.20 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.40 (+-0.65%)

N/A
FPX First Trust US Equity Opp.. 0.00 % 0.59 %

+0.12 (+-0.65%)

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.04 (+-0.65%)

USD 0.08B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.66 (+-0.65%)

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-0.23 (-0.65%)

N/A
PXLG Invesco S&P 500 GARP ETF 0.00 % 0.39 %

+0.08 (+-0.65%)

N/A
HERS-B:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+-0.65%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+-0.65%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.13 (-0.65%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+-0.65%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.14 (-0.65%)

N/A
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

-0.07 (-0.65%)

CAD 0.18B
XMY:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

-0.10 (-0.65%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

+0.41 (+-0.65%)

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

+0.02 (+-0.65%)

N/A
HERS:CA 0.00 % 0.62 %

N/A

N/A
ENTR ERShares Entrepreneurs ET.. 0.00 % 0.49 %

N/A

USD 0.11B
FPX:LSE First Trust Global Funds .. 0.00 % 0.00 %

+33.00 (+-0.65%)

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

-0.37 (-0.65%)

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
EMEH:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

N/A

N/A
GSDE:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.08 (+-0.65%)

N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

-5.20 (-0.65%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
DWEQ 0.00 % 0.00 %

N/A

N/A
LYFE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.27% 64% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.27% 64% D 74% C
Trailing 12 Months  
Capital Gain 30.49% 78% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.49% 78% C+ 79% B-
Trailing 5 Years  
Capital Gain 220.79% 92% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 220.79% 92% A 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 27.25% 78% C+ 84% B
Dividend Return 27.25% 78% C+ 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.90% 82% B 60% D-
Risk Adjusted Return 88.18% 99% N/A 95% A
Market Capitalization 42.08B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.10 21% 32%
Price/Book Ratio 3.82 39% 28%
Price / Cash Flow Ratio 23.36 3% 12%
Price/Free Cash Flow Ratio 19.42 2% 13%
Management Effectiveness  
Return on Equity 15.28% 98% 85%
Return on Invested Capital 14.45% 89% 84%
Return on Assets 7.74% 98% 92%
Debt to Equity Ratio 7.63% 56% 74%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.